Search Results - yvonne+chen

8 Results

Sort By:

Methods to Improve Chimeric Antigen Receptor (CAR)-T Cell Efficacy Through Rational Sequence and Structural Modifications (UCLA Case No. 2020-497)

UCLA researchers in the Department of Microbiology, Immunology & Molecular Genetics have developed novel engineering methodologies for CAR molecules that overcome the tonic signaling process that leads to T cell exhaustion and poor therapy efficacy. Background: Immunotherapy has become a highly effective method to combat cancer that enhances a...

Published: 9/30/2024 | Inventor(s): Yvonne Chen

Keywords(s): Cancer Immunotherapy

Category(s): Therapeutics > Oncology > Oncology Immunotherapy

Engineered T Cells Capable of Simultaneous Tumor Targeting and Alteration of Tumor Microenvironment Through Vasculature Normalization (UCLA Case No. 2023-264)

UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have built a series of chimeric antigen receptor (CAR)-T cells that target different antigens and secrete different anti-angiogenic proteins. Additionally, researchers also constructed bispecific CARs that respond to tumor antigen and pro-angiogenic molecules. BACKGROUND:...

Published: 6/27/2024 | Inventor(s): Yvonne Chen

Keywords(s): Cancer, Cancer Immunotherapy, CAR-T cell therapy, immunosuppression, Immunosuppressive Drug, Immunotherapy, solid tumors, Tumor microenvironment, tumor vasculature, VEGF

Category(s): Therapeutics > Oncology

Novel Anti-mesothelin CAR for Use in Engineered Cell Therapies (UCLA Case No. 2023-281)

UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a nanobody-based CAR T cell platform with increased stability and cross-immunogenicity between human and mouse antigens. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered T cells to target and clear cancer cells....

Published: 6/28/2024 | Inventor(s): Yvonne Chen

Keywords(s): Cancer, CAR-T cell platform, CAR-T cell therapy, cell engineering, Immunotherapy, Mesothelin, nanobody, Nanoparticle

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

2022-190 Pharmacological Modulation of Chimeric Antigen Receptor (CAR)-T Cell Signaling Pathways to Improve Tumor-Killing Efficacy

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have developed a novel chimeric antigen receptor (CAR)-T cell manufacturing process to prevent premature CAR-T cell dysfunction and enhance CAR-T cell durability and potency. BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy is an emerging pillar...

Published: 8/20/2023 | Inventor(s): Yvonne Chen

Keywords(s):

Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

2019-839 Self-Modulating T Cells with Robust Anti-Tumor Efficacy and Reduced Propensity for Triggering Severe Cytokine Release Syndrome

SUMMARY: Researchers from UCLA’s Department of Microbiology, Immunology and Molecular Genetics have developed methods for generating self-modulating CAR-T cells which retain robust anti-tumor function whilst having reduced adverse side effects relating to cytokine release syndrome. BACKGROUND: The immunotherapy approach of T-cell engineering...

Published: 9/11/2023 | Inventor(s): Yvonne Chen

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Autoimmune, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

2015-671 Underground Shafts for Hydrogen Storage

SummaryResearchers at UCLA have developed an underground drilled shaft concept for storage of hydrogen or other gases.BackgroundOne challenge in creating a hydrogen economy is developing hydrogen gas storage solutions. Increased interest has helped the global hydrogen storage market grow to $2.6 billion in 2016, and it is expected to reach over $5...

Published: 7/19/2023 | Inventor(s): Adrienne Lavine, Hossein Kavehpour, Dante Simonetti, Richard Wirz, Chen Chen, Gabriela Bran, Gopinath Warrier, Hamarz Aryafar, Jonathon Kennedy, Joshua Jordan, Keith Lovegrove

Keywords(s): Energy & Water

Category(s): Energy & Environment > Energy Generation > Solar, Energy & Environment > Energy Storage

IL-6 Receptor Alpha-Binding Protein and its Use In Controlling Cytokine Release Syndrome In Immunotherapy (UCLA Case No. 2017-453)

SUMMARY UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a novel protein that binds to and inhibits human IL-6 receptor alpha (IL-6Rα), which can be used to modulate and/or prevent cytokine release syndrome in immunotherapy. BACKGROUND Severe cytokine release syndrome (CRS), or a sudden and dramatic...

Published: 8/31/2023 | Inventor(s): Yvonne Chen, Meng-Yin Lin

Keywords(s): Immunotherapy, Life Science Research Tools, Oncology Immunotherapy

Category(s): Life Science Research Tools, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy

2015-390 Bispecific, OR-Gate Chimeric Antigen Receptor Responsive to CD19 and CD20

Bispecific, Or-Gate Chimeric Antigen Receptor Responsive To CD19 And CD20SUMMARYUCLA research have developed a CD19‐OR‐CD20 chimeric antigen receptor (CAR) that can trigger T‐cell activation upon detection of CD19 or CD20.BACKGROUNDConventional T‐cell therapy utilizes single‐input anti‐CD19 CAR-T cells. Multiple clinical trials have reported remarkable...

Published: 9/18/2023 | Inventor(s): Yvonne Chen, Eugenia Zah, Michael Jensen, Anne Deepika Silva-Benedict

Keywords(s): Immunotherapy, Oncology Immunotherapy

Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy